COMMUNIQUÉS West-GlobeNewswire

Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor
02/10/2018
Study results published in Clinical Cancer Research shows that DNA immunotherapy approach drove T cell infiltration in tumors PLYMOUTH MEETING, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ [...]
BioCorRx Provides BICX102 Grant Update
02/10/2018
ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided [...]
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
02/10/2018
Positive Results from AVERTS-2 Phase 3 Clinical Trial will Support Submission for U.S. Registration and Provide Basis for Ongoing Additional Phase 3 Trial SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. ( [...]
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
02/10/2018
New research further supports the long-term efficacy and well-characterized safety of leading MS products N ovel data generation initiatives aim to improve outcomes and support the continued move toward precision [...]
Transactions in relation to share buyback program
02/10/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Assembly Biosciences Announces Oral Presentation at 2018 AASLD
02/10/2018
SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases [...]
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
02/10/2018
CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold [...]
Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure
02/10/2018
NEWTOWN, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the [...]
Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society
02/10/2018
CRANBURY, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included [...]
Vistin Pharma ASA : Prospectus Summary for transfer of listing from Oslo Axess to Oslo Børs
02/10/2018
Oslo, Norway, 2 October 2018 Reference is made to the announcement on 26 September 2018 regarding Oslo Børs' resolution to admit the shares in Vistin Pharma ASA to listing on Oslo Børs. Vistin Pharma ASA today published [...]
ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
02/10/2018
LOS ANGELES, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU [...]
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
02/10/2018
Data from Study Expected in Q1 2019 MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare [...]
Clementia amorce un essai clinique de phase 1 portant sur une formulation de gouttes oculaires à base de palovarotène mené chez des volontaires sains
02/10/2018
Disponibilité prévue des données de l’étude : T1 2019 MONTRÉAL, 02 oct. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des traitements [...]
Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
02/10/2018
Berlin, Germany, 2 October 2018 - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural [...]
Press release: Terveystalo's well-being services grow: Fysiatrinen osaamiskeskus Prima Oy to become part of Terveystalo
02/10/2018
On September 28, Terveystalo signed a contract on acquiring the operations of Fysiatrinen osaamiskeskus Prima Oy. The company's employees will be transferred to Terveystalo as old employees and the operations will [...]
People with diabetes may achieve improved glycaemic control with Tresiba® versus glargine U100, without an increase in hypoglycaemia
02/10/2018
Berlin, Germany, 2 October 2018 - According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA 1c ) with Tresiba ® (insulin [...]
Ryzodeg® offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart
02/10/2018
Berlin, Germany, 2 October 2018 - When treated with once-daily Ryzodeg ® , people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily [...]
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
02/10/2018
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic [...]
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
02/10/2018
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes Funding enables further acceleration of commercial expansion and R&D programs EUR 3.5 million of first tranche of [...]

Pages